12 March 2024
12 March 2024
MS has gained access to Harpoon's portfolio of T-cell engagers, including MK-6070.
Wegovy can now be used to reduce the risk of major cardiovascular events in obese or overweight patients with heart disease.
The approval is backed by data from a Phase III clinical trial in 539 adult subjects aged between 18 and 75 years.
The FDA accepted the new drug application (NDA) for GA Depot 40mg for review in August 2023.
The FDA is still likely to approve donanemab, however, the delay will benefit Eisai and Biogen in allowing Leqembi to gain greater traction in the Alzheimer's market.
The race for the first FDA-approved cell therapy for patients with heart failure heats up.
Cresemba will enjoy seven years and six months of market exclusivity for the treatment of invasive aspergillosis and invasive mucormycosis.
AbCellera will receive upfront and milestone payments from Biogen under the deal.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
